<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992507</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-20306</org_study_id>
    <secondary_id>NCI-2021-05849</secondary_id>
    <nct_id>NCT04992507</nct_id>
  </id_info>
  <brief_title>Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study</brief_title>
  <official_title>The Impact of Total Intravenous Anesthesia Following Cancer Surgery (TIVACS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trials studies the impact of total intravenous anesthesia (TIVA) following&#xD;
      cancer surgery. Surgery and the anesthesia delivered causes physiologic stress and trauma&#xD;
      resulting in immune suppression. TIVA is an alternative method of general anesthesia that has&#xD;
      several benefits over volatile inhalation agents such as reducing nausea, vomiting, and&#xD;
      opioid consumption, and promotes earlier return of bowel function following surgery. In&#xD;
      addition, TIVA is less immunosuppressive than inhalational agents and has been shown to&#xD;
      decrease cancer cell proliferation, migration, and metastasis formation. Giving TIVA during&#xD;
      cancer-directed abdominal surgery may decrease the immunosuppressive state in the&#xD;
      peri-surgical period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the impact of anesthetic agent on inflammation and immunosuppression among&#xD;
      patients undergoing abdominal cancer surgery.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the impact of anesthetic choice on short-term anesthetic and surgical&#xD;
      outcomes.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients undergo surgical resection with TIVA.&#xD;
&#xD;
      ARM II: Patients undergo surgical resection with inhaled volatile anesthetics.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of anesthetic agent on inflammation and immunosuppression</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>All data analysis will use Student's t-test, Chi2 test and multivariable regression analysis using linear mixed model. The incidence of these outcomes will also be associated with NET levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of anesthetic choice on short-term anesthetic and surgical outcomes</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>All data analysis will use Student's t-test, Chi2 test and multivariable regression analysis using linear mixed model. The incidence of these outcomes will also be associated with NET levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (surgical resection with TIVA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo surgical resection with TIVA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (surgical resection with inhaled volatile anesthetics)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo surgical resection with inhaled volatile anesthetics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anesthesia Procedure</intervention_name>
    <description>Given TIVA</description>
    <arm_group_label>Arm I (surgical resection with TIVA)</arm_group_label>
    <other_name>Anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>General Anesthesia Procedure</intervention_name>
    <description>Given inhaled volatile anesthetics</description>
    <arm_group_label>Arm II (surgical resection with inhaled volatile anesthetics)</arm_group_label>
    <other_name>General Anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection</intervention_name>
    <description>Undergo surgical resection</description>
    <arm_group_label>Arm I (surgical resection with TIVA)</arm_group_label>
    <arm_group_label>Arm II (surgical resection with inhaled volatile anesthetics)</arm_group_label>
    <other_name>Surgical Resection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults: &gt;= 18 years&#xD;
&#xD;
          -  Diagnosed with pancreatic adenocarcinoma&#xD;
&#xD;
          -  Presented for surgery between January 1, 2021 and December 31, 2023&#xD;
&#xD;
          -  Able to provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergies to study anesthetic - intravenous Propofol, or a history of malignant&#xD;
             hyperthermia to volatile inhaled anesthetics&#xD;
&#xD;
          -  Prisoner status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aslam Ejaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>The Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Aslam Ejaz, MD</last_name>
      <phone>614-293-7171</phone>
      <email>Aslam.Ejaz@osum.edu</email>
    </contact>
    <investigator>
      <last_name>Aslam Ejaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Aslam Ejaz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

